{"id":161158,"date":"2024-05-15T07:01:00","date_gmt":"2024-05-15T11:01:00","guid":{"rendered":"https:\/\/44.250.171.167\/?p=161158"},"modified":"2024-05-15T07:01:01","modified_gmt":"2024-05-15T11:01:01","slug":"neuland-laboratories-limited-q4-fy24-earnings-conference-call-insights","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/neuland-laboratories-limited-q4-fy24-earnings-conference-call-insights\/","title":{"rendered":"Neuland Laboratories Limited Q4 FY24 Earnings Conference Call Insights"},"content":{"rendered":"<p><strong>Key highlights from Neuland Laboratories Limited (NEULANDLAB) Q4 FY24 Earnings Concall<\/strong><\/p>\n<ul>\n<li><strong>Financial Performance<\/strong>\n<ul>\n<li>Total income for FY &#8217;24 was INR 1,511 crores, driven by high growth in the CMS business and better growth of the specialty PD business.<\/li>\n<li>EBITDA for FY &#8217;24 stood at INR 24.5 crores with a margin of 13.2%, an increase of 6.8% over the previous year.<\/li>\n<li>Total income for Q4 FY &#8217;24 was INR 29.4 crores, while EBITDA for Q4 FY &#8217;24 stood at INR 14.2 crores with a margin of 28.7%, a decrease of 2.2% over Q4 of the previous year.<\/li>\n<li>Profit after tax was INR 67.6 crores, compared to INR 84.5 crores in Q4 FY &#8217;23.<\/li>\n<\/ul>\n<\/li>\n<li><strong>Cost Optimization<\/strong>\n<ul>\n<li>The company continues to be mindful of managing operational costs, resulting in financial revenue.<\/li>\n<li>This ability to grow without product cost sedation is attributed to the dedication to operational efficiency and cost optimization.<\/li>\n<\/ul>\n<\/li>\n<li><strong>Debt and Capex<\/strong>\n<ul>\n<li>The company reduced its debt by INR 79.4 crores during the financial year.<\/li>\n<li>Net debt position stands at negative INR 3.6 crores, indicating a strong financial position.<\/li>\n<li>Invested INR 142.7 crores in capital expenditure during FY &#8217;24, upgrading its facilities.<\/li>\n<li>Generated a free cash flow of INR 1.4 crores in FY &#8217;24.<\/li>\n<li>Strategically optimizing operations and capital expenditure to maintain robust internal cash flow.<\/li>\n<\/ul>\n<\/li>\n<li><strong>Growth and Product Mix<\/strong>\n<ul>\n<li>Neuland achieved over 30% growth in FY &#8217;24, following 26% growth in FY &#8217;23.<\/li>\n<li>EBITDA margins also improved from 15% in FY &#8217;22 to 23% in FY &#8217;23 and further to 30% in FY &#8217;24.<\/li>\n<li>The CMS business contributed close to 50% of revenues in FY &#8217;24, growing robustly.<\/li>\n<li>The specialty GDS business grew, driven by molecules like Paliperidone, while there was a slight decline in Prime GDS.<\/li>\n<li>Key molecules contributing to Prime GDS business were mirtazapine and escitalopram.<\/li>\n<\/ul>\n<\/li>\n<li><strong>Capacity Expansion and Outlook<\/strong>\n<ul>\n<li>Actively investing in long-term growth capex, as announced during the year.<\/li>\n<li>The company is creating additional capacities and capabilities to reach scale in new and existing molecules.<\/li>\n<li>The company expects moderation in revenue growth and normalization of margins due to investments and input cost increases in the short run.<\/li>\n<li>The long-term potential is exciting, led by commercialization of molecules and addition of new business.<\/li>\n<li>The company expects FY &#8217;25 to be a year of normalized revenue growth due to investments and input cost increases.<\/li>\n<li>The company expects biotech funding and the biosecurity bill may boost revenue from early-stage projects.<\/li>\n<li>Over a medium-term horizon of four to five years, the company targets a 20% growth CAGR.<\/li>\n<li>The baseline capex guidance remains at INR 100 crores plus for FY &#8217;25 and FY &#8217;26.<\/li>\n<li>The company aims to allocate no more than 60% of operating cash towards capex, but is willing to breach this benchmark based on available opportunities.<\/li>\n<li>FY &#8217;24 margins were better than expected, and the company expects some normalization in FY &#8217;25.<\/li>\n<\/ul>\n<\/li>\n<li><strong>Product Pipeline<\/strong>\n<ul>\n<li>NEULANDLAB saw a significant jump in the Phase II molecule pipeline during the current year.<\/li>\n<li>The total number of projects\/molecules has not grown much from FY &#8217;20 to FY &#8217;24 (76 in FY &#8217;20 to 88 in FY &#8217;24) compared to the preceding two years.<\/li>\n<li>The company is focused on both the number of projects and the quality of projects, aiming for high-value opportunities.<\/li>\n<li>New project inflows were impacted by the biotech funding crunch a year ago, but a steady increase in new opportunities and RFPs is now being observed.<\/li>\n<\/ul>\n<\/li>\n<li><strong>Peptide Pipeline<\/strong>\n<ul>\n<li>The company expects to file one peptide molecule&#8217;s DMF in calendar year 2024, which is on track.<\/li>\n<li>Another GLP-1 peptide molecule&#8217;s DMF filing is expected in 2026, presenting a significant opportunity, especially in the generic space.<\/li>\n<li>The company continues to see increased interest from generic customers for peptide molecules.<\/li>\n<\/ul>\n<\/li>\n<li><strong>GLP-1 Opportunity<\/strong>\n<ul>\n<li>The GLP-1 CDMO opportunity is limited as innovators are securing their own API supply chains.<\/li>\n<li>GLP-1 peptides are expected to have higher volumes, requiring significant infrastructure and capacity planning.<\/li>\n<li>Some unpredictability exists around the IP landscape and innovators&#8217; strategies for GLP-1 products.<\/li>\n<li>Opportunities may also arise for fragments and building blocks of GLP-1 peptides on the CDMO side.<\/li>\n<\/ul>\n<\/li>\n<li><strong>Biosecurity Act<\/strong>\n<ul>\n<li>The current status of the proposed Biosecurity Act in the U.S. is uncertain.<\/li>\n<li>The narrative around the Biosecurity Act is favorable, leading to increased conversations and interest from American companies towards Neuland and other CDMOs.<\/li>\n<li>The company is waiting to see if this translates into actual business opportunities.<\/li>\n<\/ul>\n<\/li>\n<li><strong>Commercialized API Growth<\/strong>\n<ul>\n<li>The company has not lost any customers in the past, and its custom manufacturing customers&#8217; patents will not expire until 2030.<\/li>\n<li>NEULAND clarified that while it has built a portfolio of 18 commercialized API\/intermediates, the key molecules contributing substantially to commercial revenues are around 4-5.<\/li>\n<li>Expects the count of commercialized APIs to grow gradually, but providing specific quarter-on-quarter guidance is challenging.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Key highlights from Neuland Laboratories Limited (NEULANDLAB) Q4 FY24 Earnings Concall Financial Performance Total income for FY &#8217;24 was INR 1,511 crores, driven by high growth in the CMS business and better growth of the specialty PD business. EBITDA for FY &#8217;24 stood at INR 24.5 crores with a margin of 13.2%, an increase of [&hellip;]<\/p>\n","protected":false},"author":1767,"featured_media":154818,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[9825,392,5747],"tags":[10169,9873,1115],"class_list":["post-161158","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-earnings-call-highlights","category-earnings","category-healthcare-stocks","tag-earnings","tag-laboratories","tag-pharmaceuticals"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/CC_Image_1.jpg","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":161267,"url":"https:\/\/alphastreet.com\/india\/ideaforge-technology-ltd-q4-fy24-earnings-conference-call-insights\/","url_meta":{"origin":161158,"position":0},"title":"ideaForge Technology Ltd Q4 FY24 Earnings Conference Call Insights","author":"Praveen","date":"May 16, 2024","format":false,"excerpt":"Key highlights from ideaForge Technology Ltd (IDEAFORGE) Q4 FY24 Earnings Concall U.S. Market Entry Promising progress in expanding global footprint and exploring new market opportunities in U.S. Conducted beta testing with law enforcement agencies, successfully carrying out real-life missions. Differentiated experience compared to existing drone inventory, contributing to product-market fit.\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/CC_Image_1.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/CC_Image_1.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/CC_Image_1.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/CC_Image_1.jpg?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":161219,"url":"https:\/\/alphastreet.com\/india\/clean-science-and-technology-limited-q4-fy24-earnings-conference-call-insights\/","url_meta":{"origin":161158,"position":1},"title":"Clean Science and Technology Limited Q4 FY24 Earnings Conference Call Insights","author":"Praveen","date":"May 16, 2024","format":false,"excerpt":"Key highlights from Clean Science and Technology Limited (CLEAN) Q4 FY24 Earnings Concall Volume Recovery Recorded volume growth on annual and sequential basis in Q4 FY'24. Volumes recovered during H2 FY'24 after declining in H1. Volumes surpassed previous levels in Q4 FY'24. Financial Performance Sales grew 16% Q-o-Q, driven by\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/CC_Image_1.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/CC_Image_1.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/CC_Image_1.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/CC_Image_1.jpg?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":161359,"url":"https:\/\/alphastreet.com\/india\/hindustan-aeronautics-limited-q4-fy24-earnings-conference-call-insights\/","url_meta":{"origin":161158,"position":2},"title":"Hindustan Aeronautics Limited Q4 FY24 Earnings Conference Call Insights","author":"Praveen","date":"May 20, 2024","format":false,"excerpt":"Key highlights from Hindustan Aeronautics Limited (HAL) Q4 FY24 Earnings Concall Revenue Growth Revenues surged to new heights in FY 2023-24 at INR 30,381 crores, a 13% increase from the previous year. Achieved double-digit growth target a year in advance, initially guided for FY 2024-25 onwards. Strong order book and\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/CC_Image_1.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/CC_Image_1.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/CC_Image_1.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/CC_Image_1.jpg?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":161429,"url":"https:\/\/alphastreet.com\/india\/tracxn-technologies-ltd-q4-fy24-earnings-conference-call-insights\/","url_meta":{"origin":161158,"position":3},"title":"Tracxn Technologies Ltd Q4 FY24 Earnings Conference Call Insights","author":"Praveen","date":"May 21, 2024","format":false,"excerpt":"Key highlights from Tracxn Technologies Ltd (TRACXN) Q4 FY24 Earnings Concall Financials Q4 FY24 revenue from operations: INR 20.3 crores. Q4 FY24 total income: INR 21.6 crores. FY24 revenue from operations: INR 82.8 crores (6% YoY growth). FY24 total income: INR 87 crores (7.2% YoY growth). Q4 FY24 EBITDA: INR\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/CC_Image_1.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/CC_Image_1.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/CC_Image_1.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/CC_Image_1.jpg?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":161197,"url":"https:\/\/alphastreet.com\/india\/apar-industries-limited-q4-fy24-earnings-conference-call-insights\/","url_meta":{"origin":161158,"position":4},"title":"Apar Industries Limited Q4 FY24 Earnings Conference Call Insights","author":"Praveen","date":"May 15, 2024","format":false,"excerpt":"Key highlights from Apar Industries Limited (APARINDS) Q4 FY24 Earnings Concall Financial Performance Q4 FY24 consolidated revenue grew 9% YoY to INR 4,455 crores. EBITDA increased 3% YoY to INR 457 crores with 10.3% margin. PAT declined 3% YoY to INR 236 crores. FY24 consolidated revenue at all-time high of\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/CC_Image_1.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/CC_Image_1.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/CC_Image_1.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/CC_Image_1.jpg?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":160721,"url":"https:\/\/alphastreet.com\/india\/newgen-software-technologies-limited-q4-fy24-earnings-conference-call-insights\/","url_meta":{"origin":161158,"position":5},"title":"Newgen Software Technologies Limited Q4 FY24 Earnings Conference Call Insights","author":"Praveen","date":"May 1, 2024","format":false,"excerpt":"Key highlights from Newgen Software Technologies Limited (NEWGEN) Q4 FY24 Earnings Concall Revenue Growth Revenue increased by 28% year-over-year to INR 1,244 crores. Witnessed strong growth in EMEA, 39% and India, 33% markets. Secured largest project worth INR 97 crores in APAC region. Increased number of customers with billing over\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/CC_Image_1.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/CC_Image_1.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/CC_Image_1.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/CC_Image_1.jpg?resize=700%2C400&ssl=1 2x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/161158","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1767"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=161158"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/161158\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/154818"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=161158"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=161158"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=161158"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}